Results of Method 1.

<p>Abbreviations. NS: nephrotic syndrome.</p><p>Results of Method 1.</p

Quantification of the Tc-99m uptake in the nephrotic syndrome and non- nephrotic syndrome groups on the posterior view.

<p>A: right kidney, B: left kidney.</p

Characteristics of 17 patients.

<p>*P < 0.05 vs. NS group,</p><p>⁺P < 0.01 vs. NS group.</p><p>Proteinuria; (-): ~9 mg/dl, (±): 10~29 mg/dl, (1+): 30~99 mg/dl, (2+): 100~299 mg/dl, (3+): 300~999 mg/dl, (4+): 1000 mg/dl~</p><p>Abbreviations. NS: nephrotic syndrome, M: male, F: female, BMI: body mass index, U-pro/cr: urinary protein-creatinine ratio, TP: serum total protein, Alb: serum albumin, T-cho: serum total cholesterol,</p><p>LDL-C: serum low-density lipoprotein cholesterol, TG: serum triglycerides, Cr: serum creatinine, ND: no data.</p><p>Characteristics of 17 patients.</p

Sequential changes in the %ID in the main organs after the injection of ^99mTc-HSAD in a healthy adult.

<p>Reproduced from Tamaki N et al. [<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0123036#pone.0123036.ref003" target="_blank">3</a>]. Abbreviations. %ID: % injected dose.</p

Definition of Dense Kidney.

<p>We defined the presence of a more intense uptake in the kidney (<i>white arrow</i>) than the liver (<i>black arrow</i>) on the anterior view 24 hours after ^99mTc-HSAD administration as Dense Kidney (+) (A), the same uptake in the liver and kidney as Dense Kidney (±) (B) and a more intense uptake in the liver than the kidney as Dense Kidney (-) (C).</p

Quantification of the Tc-99m uptake in the nephrotic syndrome and non- nephrotic syndrome groups on the anterior view.

<p>A: right kidney, B: left kidney.</p

Results of Method 1.

<p>Abbreviations. NS: nephrotic syndrome.</p><p>Results of Method 1.</p

Baseline characteristics of patients.

<p>ARB, angiotensin II receptor blocker; IQR, interquartile range.</p><p>Baseline characteristics of patients.</p

Changes in the number of small intestinal mucosal breaks from baseline to posttreatment.

<p>Results were analyzed by the Wilcoxon signed-rank test.</p

Changes in the levels of hemoglobin and albumin after treatment with placebo or rebamipide.

<p>Results are expressed as medians and interquartile ranges (IQRs)</p><p>Changes in the levels of hemoglobin and albumin after treatment with placebo or rebamipide.</p